NovaBridge Biosciences (NBP) Cash & Equivalents (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Cash & Equivalents for 8 consecutive years, with $210.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 208.56% year-over-year to $210.6 million; the TTM figure through Dec 2025 stood at $210.6 million (up 208.56% YoY), while the FY2025 annual figure was $210.6 million, up 208.56% from the prior year.
• Cash & Equivalents declined to $210.6 million in Q4 2025 per NBP's latest filing, from $228.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $672.5 million in Q2 2021 and bottomed at $53.6 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $293.0 million across 5 years, with a median of $228.1 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 77.05% — and 2025, when it surged 208.56%.
• NovaBridge Biosciences' Cash & Equivalents stood at $551.1 million in 2021, then fell by 18.0% to $451.9 million in 2022, then plunged by 34.18% to $297.4 million in 2023, then slumped by 77.05% to $68.3 million in 2024, then soared by 208.56% to $210.6 million in 2025.
• Business Quant data shows NBP's Cash & Equivalents at $210.6 million in Q4 2025, $228.1 million in Q3 2025, and $165.4 million in Q2 2025.